| Accession | SAMC4113721 |
|---|---|
| Accession in Other Database | GSA-Human: HRS1347889 |
| Sample name | A630 |
| Title | Bulk sequencing before Aumolertinib treatment for NSCLC |
| Sample type | Human sample |
| Organism | Homo sapiens |
| Description | Aumolertinib baseline |
| Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA008462 in the GSA-Human system. |
| Release date | 2025-03-12 |
| BioProject Accession | PRJCA013411 |
| Submitter | Peng Zhang (zhangpeng1121@tongji.edu.cn) |
| Organization | Shanghai Pulmonary Hospital Tongji University |
| Submission date | 2024-09-04 |
| Resource name | Description |
|---|---|
| GSA-Human (1) | - |
| HRA008462 (Controlled Access) | This phase II trial evaluated neoadjuvant Aumolertinib, a third-generation EGFR-TKI, for inoperable stage III EGFR-mutant NSCLC. Among 51 patients treated, the objective response rate was 70.6%, with 45.1% converting to operable disease and undergoing successful R0 resection. Five patients had major pathological responses, and three had complete responses. RNA-sequencing revealed increased CD8+ T-cell infiltration post-treatment, particularly in tumors with Ex19-Del mutations. Aumolertinib demonstrated promising efficacy, a high surgical conversion rate, and a tolerable safety profile. |